How do I find clinical trials in the UK?

Use TrialConnect to search by condition, location, or eligibility. We index over 29,000 UK clinical trials from ClinicalTrials.gov, updated daily. Enter your condition and we show matching trials near you.

Are there paid clinical trials in the UK?

Yes. Healthy volunteers can earn £500–£3,000 for Phase 1 and bioequivalence studies. TrialConnect lists paid research studies at UK research units in London, Leeds, Nottingham, and more.

What conditions have clinical trials available?

TrialConnect covers 41 conditions including breast cancer, lung cancer, diabetes, heart failure, COPD, multiple sclerosis, Parkinson's disease, Crohn's disease, and many more.

Is TrialConnect free?

Yes. TrialConnect is completely free for patients. We are not affiliated with the NHS or NIHR. Data is sourced from ClinicalTrials.gov.

Am I eligible for a clinical trial?

Each trial has specific eligibility criteria including age, condition, medical history, and current treatments. TrialConnect shows you trials that may match your situation, but only the trial team can confirm eligibility.

A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction

View on ClinicalTrials.gov ↗

At a glance

What the study gets you: Access to the study treatment being tested
Type of study: Interventional (receives a drug or procedure)
Time in hospital: In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention: Finerenone (Kerendia, BAY94-8862) (drug), Placebo (drug)
How long the study runs: Study runs about 49 months (dates as stated)
About the drug or intervention: Finerenone (Kerendia, BAY94-8862) — drug: Finerenone in different doses, treatment duration will be 90±3 days · Placebo — drug: Placebo to finerenone, treatment duration will be 90±3 days
Patient visit burden: Not specified by the sponsor

Type of study: Testing a treatment
Ages: 6 Months to 17 Years
Who: All
Number of participants: 111
Started: 2025-11-19
Last checked: 2026-06

Plain English Summary

What is this study?

• Testing a new treatment for left ventricular systolic dysfunction
• Phase3 - 111 participants
• Researchers are looking for a better way to treat children who have heart failure with left ventricular systolic dysfunction (LVSD)

Who can take part?

• Ages 6 Months to 17 Years
• Diagnosed with left ventricular systolic dysfunction

Where?

• Leicester - University Hospitals of Leicester NHS Trust | Leicester Children's Hospital - Children's Research Facility
• Liverpool - Alder Hey Children's NHS Foundation Trust | Alder Hey Children's Hospital - Clinical Research Facility
• Belfast - Belfast Health and Social Care Trust | Royal Belfast Hospital for Sick Children - Paediatric Cardiology
• Glasgow - NHS Greater Glasgow and Clyde | Royal Hospital for Children - Glasgow Clinical Research Facility
• +3 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

Researchers are looking for a better way to treat children who have heart failure with left ventricular systolic dysfunction (LVSD). Heart failure is a serious condition where the heart is unable to pump enough blood to meet the body's needs. This can lead to symptoms like shortness of breath, fatigue, and poor growth in children. The study treatment, finerenone (also called BAY94-8862), works by blocking a protein involved in inflammation, scarring, and thickening of the heart and blood vessels. This may help the heart to pump blood more effectively. This is the first study to explore its use specifically for children with heart failure and LVSD. The main purpose of this study is to learn if finerenone works to help the heart compared to placebo in children with heart failure and LVSD. For this, the researchers will collect and analyze data on the levels of a protein called NT-proBNP in the blood, which indicates heart stress, and monitor the safety of the treatment. The study will include children with heart failure and LVSD aged from 6 months to less than 18 years. The study participants will be randomly assigned to one of two treatment groups. Based on their group, they will receive either finerenone or a placebo for a duration of 3 months. A placebo looks like a treatment but does not have any medicine in it. Throughout the study, all participants will continue to receive their standard heart failure treatments. At the start of this study, the doctors will check each participant's medical history and current medications. If participants qualify for the treatment phase, they will undergo treatment for about 90 days. During this time, they will visit the study site at least 3 times. During these visits, the participants will: * have their blood pressure, heart rate, temperature, respiratory rate, height and weight measured * have their heart examined by electrocardiogram (ECG) and echocardiogram * have blood samples taken * have physical examinations * answer questions about their medication and whether they have any adverse events, or have their parents or guardians' answers An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. After the initial three-month study, eligible participants will have the option to join a nine-month open-label extension study where all will receive finerenone. Participants who choose not to enroll in the extension will have a follow-up visit 30 days after their last treatment.

Left Ventricular Systolic DysfunctionHeart Failure (Pediatric)

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search

Age· Tell us your age for better matching

Gender· Tell us your sex for better matching

Still need:

• Tell us your age for better matching
• Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

Age: 6 Months - 17 Years
Who can join: All genders

Biomarkers mentioned

eGFR

Treatment history

Treatments you must have had:

✓ a body weight ≥ 4

What the study is looking for

✓Participants must be 6 months to \<18 years old at the time when the agreement to take part/assent is signed.
✓Left ventricular systolic dysfunction (LVSD) with left ventricular ejection fraction (LVEF) ≤ 50% at screening...
✓Elevated NT-pro BNP levels
✓\>500 ng/l for children ≥ 6 months to \< 2 years of age
✓\>300 ng/l, for children ≥ 2 years to \<18 years

Who cannot take part

✗Serum potassium:
✗\> 5.0 mmol/L for children ≥ 2 years of age at either screening or randomization visit
✗Severe kidney dysfunction with eGFR \< 30 ml/min/1.73m² at screening or randomization visit.
✗Systolic blood pressure (SBP) \< 5th percentile for age, sex and height at screening or randomization.
✗Sustained or causing symptoms arrhythmias not controlled by drug or device therapy within 30 days prior to randomization.

See the full criteria

Inclusion Criteria: * Participants must be 6 months to \<18 years old at the time when the informed consent/assent is signed. * Left ventricular systolic dysfunction (LVSD) with left ventricular ejection fraction (LVEF) ≤ 50% at screening assessed by echocardiography. * Elevated NT-pro BNP levels * \>500 ng/l for children ≥ 6 months to \< 2 years of age * \>300 ng/l, for children ≥ 2 years to \<18 years * Heart failure etiologies including congenital heart defects (CHD) with biventricular physiology and systemic LV; idiopathic cardiomyopathy (CM); familial/inherited and/or genetic CM; history of myocarditis (diagnosis of an acute episode was at least 3 months prior to randomization); neuromuscular disorder (eg, duchenne muscular dystrophy); inborn error of metabolism; mitochondrial disorder; acquired (chemotherapy, iatrogenic, infection, rheumatic, or nutritional); ischemic (eg, Kawasaki disease and postoperative heart failure \[HF\]); LV noncompaction. * Receiving standard of care (SoC) treatment for heart failure according to local guidelines or investigator´s discretion and being on a stable regimen for 30 days prior to randomization. * Study participants must have a body weight ≥ 4.0 kg at Visit 1. Exclusion Criteria: * Serum potassium: * \> 5.0 mmol/L for children ≥ 2 years of age at either screening or randomization visit * \> 5.3 mmol/L for children ≥ 6 months to \< 2 years of age at either screening or randomization visit (if estimated glomerular filtration rate \[eGFR\] \< 60 mL/min/1.73m², threshold of \> 5.0 mmol/L will be used) * Severe renal dysfunction with eGFR \< 30 ml/min/1.73m² at screening or randomization visit. * Systolic blood pressure (SBP) \< 5th percentile for age, sex and height at screening or randomization. * Sustained or symptomatic arrhythmias not controlled by drug or device therapy within 30 days prior to randomization. * Treatment with a mineralocorticoid receptor antagonist (e.g., spironolactone, eplerenone) within 30 days of randomization. * Requirement of any intravenous (IV) vasoactive agents, mechanical ventilation, mechanical circulatory support within 30 days prior to randomization. * Recent surgical procedure or other intervention to correct or palliate CHD within 3 months prior to randomization or anticipated to undergo cardiac surgery during the 3 months after randomization.

Where Is This Study? (7 UK sites)

University Hospitals of Leicester NHS Trust | Leicester Children's Hospital - Children's Research Facility

Leicester LE1 5WW, United Kingdom

Recruiting